# Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

> **NCT02235701** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

## Interventions

- **DRUG:** 170 mg/m2 aldoxorubicin
- **DRUG:** 250 mg/m2 aldoxorubicin

## Key facts

- **NCT ID:** NCT02235701
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-02
- **Primary completion:** 2018-05-01
- **Final completion:** 2018-05-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02235701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02235701, "Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02235701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*